Independent. No tobacco money. No corporate fluff.MON, AUG 24

PouchDaily

The daily pulse of the nicotine pouch market

Regulation
US

Trump's FDA pick will decide the fate of unauthorized nicotine pouches

Trump has tapped White House health aide Dr. Heidi Overton to run the FDA. She'd inherit a controversial policy that lets some unauthorized nicotine pouches stay on sale while their applications sit pending — and she hasn't said whether she'd keep it.

PouchDaily Desk·
FDAHeidi Overtonnicotine pouch regulationPMTAenforcement policyCTPMarty MakaryTrump administration

President Donald Trump has selected White House health policy adviser Dr. Heidi Overton to lead the U.S. Food and Drug Administration — putting a surgeon with no stated nicotine agenda in line to oversee the agency as it reshapes how it regulates nicotine pouches.

Bloomberg first reported the decision on 19 August 2026, with Reuters, NBC, Axios, and CBS confirming it. The nomination still needs Senate confirmation.

The pouch stakes are concrete. Overton would take over an FDA that, in May, issued new guidance setting enforcement priorities for unauthorized nicotine pouch products with pending applications — a policy that lets certain pouches stay on the market while their premarket tobacco product applications (PMTAs) remain under review. She has not said whether she will keep, tighten, or scrap it.

What happened

Trump chose Overton, the deputy director of the White House Domestic Policy Council, to succeed Marty Makary, who left the FDA in May after 13 months amid clashes with administration officials and controversy over the return of flavored vaping products to the U.S. market. Kyle Diamantas has led the agency on an acting basis since.

Overton previously worked at the America First Policy Institute. She earned her medical degree from the University of New Mexico, trained in general surgery at Johns Hopkins, and pursued clinical-investigation research training at the Johns Hopkins Bloomberg School of Public Health. She also served as a White House Fellow during Trump's first term. She has longstanding ties to Makary — the two trained at Johns Hopkins and co-authored health-policy work; the Wall Street Journal reported she defended Makary inside the administration before his departure.

Reactions split along predictable lines. Raymond James analyst Chris Meekins, a former Trump health official, told Axios that Overton has "degrees but seemingly no real experience running anything" and criticized her as a Makary protégé. Brian Blase, president of the Paragon Health Institute and a former Trump health policy adviser, called her a "great choice."

Why it matters for pouches

The FDA's Center for Tobacco Products (CTP) spent 2025 reshaping the very pipeline Overton would inherit. In May, CTP announced changes to accelerate PMTA reviews after reducing its application backlog by roughly 70% in 2025. It then issued guidance establishing enforcement priorities for certain unauthorized electronic nicotine delivery systems (ENDS) and nicotine pouch products with pending applications.

The policy allows certain unauthorized products that meet specified conditions to fall outside the FDA's current enforcement priorities while their PMTAs remain pending. Crucially, the FDA stressed these products remain unauthorized — the policy is not a signal that they will eventually be approved.

The agency is also building a public list of manufacturers and products that fall under the lower-priority enforcement policy, intended to give retailers visibility into which items the FDA generally does not intend to chase first.

This is the same enforcement-discretion landscape that public-health groups are already fighting in court — PouchDaily covered that lawsuit here. It's also the landscape where the FDA recently authorized flavored pouch products, a move the American Heart Association said "threatens to sustain youth nicotine use." Who runs the agency decides whether that direction continues, accelerates, or reverses.

What's next

Overton has not publicly outlined a tobacco or nicotine agenda, leaving it unclear whether she would maintain, expand, or alter the direction CTP has taken in recent months. If confirmed, she would take control of an FDA that has lost more than 3,000 employees, including senior officials and division heads, in the past year.

For the pouch category, three things are worth watching through confirmation:

  • The enforcement-discretion policy. Does it survive intact, get tightened, or get withdrawn?
  • The public enforcement-priority list. Does it ship on her watch, and which pouches appear on it?
  • The PMTA pipeline. The 70% backlog reduction is a Makary-era achievement; does the accelerated review pace hold under a new commissioner with no stated nicotine plan?

Her ties to Makary hint at continuity with a looser-enforcement direction — but a hint is not a policy. Until she testifies before the Senate or lays out a tobacco agenda, the pouch industry is reading tea leaves.

Compare nicotine pouch brands and prices at PouchFinder.

SOURCES: